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Matrix metalloproteinases modulated by protein
kinase Cε mediate resistin-induced migration of
human coronary artery smooth muscle cells
Qinxue Ding, PhD,a Hong Chai, MD, PhD,a Nausheen Mahmood,b Jerry Tsao,c
Daria Mochly-Rosen, PhD,d and Wei Zhou, MD,a Palo Alto, Cupertino, Berkeley, and Stanford, Calif
Background: Emerging evidence showed that resistin induces vascular smooth muscle cell (VSMC) migration, a critical
step in initiating vascular restenosis. Adhesion molecule expression and cytoskeletal rearrangement have been observed in
this progress. Given that matrix metalloproteinases (MMPs) also regulate cell migration, we hypothesized that MMPs
may mediate resistin-induced VSMC migration.
Methods: Human VSMCs were treated with recombinant human resistin at physiologic (10 ng/mL) and pathologic (40
ng/mL) concentrations for 24 hours. Cell migration was determined by the Boyden chamber assay. MMP and tissue
inhibitor metalloproteinase (TIMP) mRNA and protein levels were measured with real-time PCR and ELISA. MMP
enzymatic activity was measured by zymography. In another experiment, neutralizing antibodies against MMP-2 and
MMP-9 were coincubated with resistin in cultured VSMCs. The regulation of MMP by protein kinase C (PKC) was
determined by V1-2, a selective PKC inhibitor.
Results: Resistin-induced smooth muscle cell (SMC) migration was confirmed by the Boyden chamber assay. Forty
nanograms/milliliter resistin increased SMC migration by 3.7 fold. Additionally, resistin stimulated MMP-2 and
-MMP9 mRNA and protein expressions. In contrast, the TIMP-1 and TIMP-2 mRNA levels were inhibited by resistin.
Neutralizing antibodies against MMP-2 and MMP-9 effectively reversed VSMC migration. Furthermore, resistin
activated PKC, but selective PKC inhibitor suppressed resistin-induced MMP expression, activity, and cell migration.
Conclusions: Our study confirmed that resistin increased vascular smooth muscle cell migration in vitro. In terms of
mechanism, resistin-stimulated cell migration was associated with increased MMP expression, which was dependent on
PKC activation. (J Vasc Surg 2011;53:1044-51.)
Clinical Relevance: Resistin, secreted by adipocytes and elevated in obese patients with type II diabetes, has shown to
promote vascular smoothmuscle cell (VSMC)migration, a key step in vascular restenosis following arterial interventions.
In this study, we confirmed the migratory effect of resistin on human vascular smooth muscle cells and investigated the
mechanisms underlying this phenotypic observation: matrix metalloproteinases modulated by protein kinase C (PKC)
may mediate resistin-induced VSMC migration. Based on those mechanistic data, selective PKC inhibitor may be a
potential therapeutic strategy for treating restenosis in the group of high-risk patients with type II diabetes.
s
O
r
l
e
c
i
o
t
C
T
0Obesity continues to pose significant public health prob-
lems in the developed nations and is steadily increasing in the
developingworld. Patients with obesity are at an increased risk
of developing cardiovascular complications1,2 including ath-
erosclerosis3,4 and restenosis.5-8 Ngo et al6 demonstrated the
relationship between obesity and aortic stenosis. Nikolsky and
colleagues7 confirmed that obesity was a significant risk factor
for restenosis andmajor adverse cardiac events following bare-
metal stent placement in the TAXUS-IV trial. Other studies
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1044howed increased resistin levels in obese patients.4 Recently,
wens et al8 reported that decreased adiponectin and elevated
esistin levels are associated with poor outcomes following
ower extremity revascularization with autogenous vein. Sev-
ral adipokines, such as adiponectin and leptin, were impli-
ated in connecting obesity to vascular complications. Resistin
s a newly identified adipokine that was found increased in
bese/diabetics patients. The pathologic plasma concentra-
ion of resistin is around 40 ng/mL while its normal level is
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Volume 53, Number 4 Ding et al 1045around 10 ng/mL.8-14 Accumulating evidence suggested
that resistin may play a role in the development of vascular
complications.8,15-17 However, little is known about the
mechanisms.
Vascular smooth muscle cell (VSMC) migration is in-
volved in initiating neointimal hyperplasia18-20 and ultimately
restenosis. Two pieces of evidence from scrape-wound assay
showed that resistin promoted the VSMC migration.17,21
Mechanistically, matrix metalloproteinases (MMPs), particu-
larly MMP-2 and MMP-9, are known to be involved in
VSMCmigration22,23 and protein kinase C (PKC) can regu-
late MMP expression.24 We, therefore, hypothesize that
MMPsmaybe involved in resistin-mediatedVSMCmigration
and that PKCε, one detectable PKC isozyme in VSMCs,
might modulate MMP expression. In this study, we used
Boyden chamber assay, an alternative migration model, to
confirm that resistin at high (pathologic) concentration can
stimulate VSMC migration. We also examined the effects of
resistin on the expression of MMP-2 and -9 and activation of
PKCε. The involvements of MMPs and PKCε in resistin-
induced VSMC migration were further confirmed using spe-
cific blocking antibodies.
METHODS
Materials and reagents. Human coronary artery
smooth muscle cells (HCASMC) and smooth muscle cells
(SMC) growth medium were from Genlantis (San Diego,
Calif). Cells came at passage two and were used at passages
5 to 8. Recombinant human resistin was obtained from
EMD Biosciences Inc (San Diego, Calif). Polycarbonate
membrane transwell inserts (pore size 8.0 m) and plates
for Boyden chamber assay were from Corning Inc (Corn-
ing, NY). The Protein and RNA Isolation System kits were
obtained from Ambion (Austin, Tex). Ten percent zymo-
gram precast gels for MMP activity detection were pur-
chased from Bio-Rad (Hercules, Calif). Antibodies against
human MMP-2 and MMP-9 were from Abcam (Cam-
bridge, Mass). The enzyme-linked immunosorbent assay
(ELISA) kits for human MMP-2 and MMP-9 were from
Calbiochem (San Diego, Calif). The high capacity RNA-
to-DNA kit and power SYBR Green PCR master mix were
from Applied Biosystems (Foster City, Calif). DAPI (4,
6-diamidino-2-phenylindole), trypsin, and nonspecific im-
munoglobulin (IgG) were from Sigma (St. Louis, Mo).
PKCε antibody was fromMillipore (Billerica, Mass). Selec-
tive PKCε inhibitor εV1-2 was from Dr Daria Mochly-
Table. The primer sequences of human MMPs and TIMP
Gene name GenBank number
MMP-2 NM_004530 CAACTACAAC
MMP-9 NM_004994 GCATAAGGA
TIMP-1 NM_003254 AAGGCTCTG
TIMP-2 NM_003255 CCAAGCAGG
GAPDH NM_002046 TGCACCACC
GAPDH, Glyceraldehydes-3-phosphate dehydrogenase; MMP, matrix metaRosen’s laboratory. sSMC migration. Boyden chamber assay was em-
loyed in this study as an alternative migration model to
crape-wound assay. Serum-starved HCASMCs (1  105
ells/well) were placed into the membrane-embedded in-
ert with 1 mL of DMEM. The bottom chamber contained
mL of DMEM. Resistin (10 or 40 ng/mL) was added to
edium in the bottom chamber. After 24 hours of incuba-
ion, nonmigrated cells were scraped off from the top side of
he insert membrane. Migrated cells on the bottom side were
xed in 4% formalin in PBS, stained with DAPI, and checked
nder a fluorescent microscope. Migrated cells in each well
ere counted in four high-power (400) fields. In addition,
esistin at 40ng/mL was added to both the top and bottom
hambers to examine its chemokinetic effects on VSMCs.
Pharmacologic interventions. Drug intervention on
esistin-induced cell migration was tested using a Boyden
hamber with the addition of anti-MMP-2 and MMP-9
ntibodies, or PKCε-selective inhibitor, εV1-2.25 Anti-
MP-2, MMP-9, or nonspecific IgG (10g/mL) was
dded in the bottom chamber and preincubated for 2 hours
ith SMCs before introducing resistin (40 ng/mL). PKCε
nhibitor (1 mol/L) was also preincubated 2 hours before
he addition of resistin for 24 hours. Migrated cells in
ifferent treatments were counted in the same way as
entioned above.
Real-time polymerase chain reaction (Real time
T-PCR). Total RNA from treated HCASMCs was iso-
ated with the PARIS kit as instructed by the manufacturer.
omplementary DNA was generated by reverse transcrip-
ion from messenger RNA (mRNA) with the high capacity
NA-to-DNA kit. The power SYBR green PCRmaster mix
as used for Real time RT-PCR reaction. Glyceraldehyde-
-phosphate dehydrogenase housekeeping gene was used
s an internal control to account for variations in sample
oading. Human MMP-2, MMP-9, tissue inhibitor metal-
oproteinase (TIMP)-1, TIMP-2 and GAPDH primers
ere listed in the Table. Real-time RT-PCR was performed
n a Mastercycler RT-PCR detection system (Eppendorf,
estbury, NY). The thermal cycle conditions used for
everse transcription were as follows: 5 minutes at 25°C, 60
inutes at 37°C, and 5 minutes at 95°C. The conditions
sed for RT-PCR were as follows: 3 minutes at 95°C, 40
ycles of 20 s at 95°C, and 1minute at 60°C. Controls were
erformed with no reverse transcription (mRNA sample
nly) or no mRNA (water only) to demonstrate the speci-
city of the primers and the lack of DNA contamination in
real-time polymerase chain reaction
rd Reverse
TTCCCTCGCA GGTCACATCGCTCCAGACTTG
CGTGAATGGC CGGTGTGGTGGTGGTTGGAG
GGGCTTC GAAAGATGGGAGTGGGAACA
TTCTCGAC GACCCATGGGATGAGTGTTT
GCTTAGC GGCATGGACTGTGGTCATGAG
teinase; TIMP, tissue inhibitor metalloproteinase.s for
Forwa
TTC
CGA
AAAA
AGT
AACTamples. The relative level of target MMP (and TIMP)
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April 20111046 Ding et almRNA in each group was normalized against internal
housekeeping gene GAPDH using the calculation formula
of 2 [Ct GAPDH-CtMMP]. The target mRNA levels in drug
treated groups were further normalized against the control
group.
Enzyme-linked immunosorbent assay (ELISA).
Total cell lysates were collected and the quantification of
MMP-2 and MMP-9 proteins was carried out with the
ELISA kit according to the manufacturer’s instructions.
The assay was quantified with a spectrophotometric micro-
plate reader (iMark; Bio-Rad) at a dual wavelength of
450/595 nm. Data were presented as a percentage of
controls.
Gelatin zymography. Equal amounts of cell lysates
(20-g protein per lane) were analyzed by gel zymography
on 10% zymogram precast gels. Protein-embedded gels
were incubated in 2.5% Triton X-100 for 30 minutes. Gels
were then incubated in the developing buffer (50 mM
Tris-HCl, pH 7.8, 200mMNaCl, 5 mMCaCl2, and 0.02%
Brij 35) for 16 hours at 37°C to enable MMPs cleaving
activity. After rinsing in water, each gel was stained with
Coomassie blue for 2 hours and destained in 10% ethanol,
5% acetic acid for 24 to 36 hours. Proteolytic activities of
MMPs were detected by clear bands which indicated the
lysis of the substrate. MMP activity quantification was
performed with NIH ImageJ software program.
Membrane-bound PKC determination. Activation
of PKCε, as measured by its translocation to the membrane
fraction was determined by Western blot of the membrane
extraction of HCASMCs. Briefly, 80% to 90% confluent
HCASMCs were starved in serum-free DMEM for 24
hours. Starved cells were then treated with vehicle (0.9%
normal saline), resistin (40 ng/mL), or resistin plus PKCε
inhibitor (1mol/L, 2 hours prior to resistin administra-
tion) for another 24 hours. Cellular membrane extraction
and Western blot were conducted as described by Christo-
pher et al.26 The dilution ratios of PKCε primary antibody
and corresponding secondary antibody were 1:1000 and
1:5000, respectively. Immunoreactive bands were visual-
ized with the use of a chemiluminescence reagent (Pierce
ECL Western Blotting Substrate; Pierce, Rockford, Ill)
according to the manufacturer’s protocol. Densitometric
Fig 1. In vitro effect of resistin on human coronary art
Two concentrations of resistin at physiologic (10 ng/m
TNF- was used as a positive control. Values are expresse
mean  SEM of quadruplicate determinations.analysis was performed using the NIH ImageJ program. aStatistical analysis. Concentration-dependent data
rom RT-PCR, ELISA, and cell migration were com-
ared by one-factor analysis of variance (ANOVA); drug
nterference data from antibody blocking and PKCε
nhibitor experiments were analyzed using two-factor
NOVA. Statistical significance was considered if the P
alue was .05.
ESULTS
Effect of resistin on HCASMC migration. The ef-
ect of resistin on SMC migration was studied in the Boy-
en chamber assay. Cells were counted and averaged from
our randomly observed fields. As shown in Fig 1, the
verage numbers of migrated SMCs in the control, 10
g/mL, and 40 ng/mL of resistin groups were 9.4 (1.5),
1.7 (0.7), and 35.0 (2.3), respectively. This reflected a
.2-fold increase in cell migration after treatment with 10
g/mL resistin (P  .05) and a 3.7-fold increase after
reatment with 40 ng/mL resistin (P  .001). We used
NF- as a positive control, which significantly induced
ell migration at 10 ng/mL (P  .001).
Effect of resistin on MMP-2 and MMP-9 expres-
ion in VSMCs. SMCs were treated with 10 or 40 ng/mL
f resistin for 24 hours. Cellular MMP-2 and -9 were
easured on both mRNA and protein levels. As shown in
ig 2,Aand B, resistin induced an increase inMMPmRNA
xpression in a concentration-dependent manner. The
MP-2 mRNA levels after 10 and 40 ng/mL of resistin
reatments were 130.3% (4.5%) (P  .01) and 159.7%
21.7%) compared with the control (P  .001); the
ost-treatment MMP-9 mRNA levels were 124.2%
7.1%) (P  .01) and 132.8% (5.4%) compared with
he control (P  .01). The effects of resistin on protein
xpression are shown in Fig 2, C and D. MMP-2 protein
evels after drug treatment were 121.6% (3.6%) and
28.7% (3.1%) compared with the control (P .01); the
MP-9 protein levels were 111.1% (3.0%) and 130.6%
3.3%) compared with the control (P  .01). Regression
nalysis showed positive and significant correlations be-
ween resistin concentration and MMP expression. The
orrelation coefficients between resistin concentrations and
MP-2 and MMP-9 protein levels were 0.73 (P  .01)
ooth muscle cell migration in Boyden chamber assay.
d pathologic (40 ng/mL) concentrations were tested.
he number of migrated cells, and each bar represents theery sm
L) an
d as tnd 0.96 (P  .001), respectively.
u
n
a
M
(
(
s
c
c
i
s
H
P
rmina
inati
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 4 Ding et al 1047Effect of resistin on TIMP-1 and TIMP-2 expres-
sion in VSMCs. As shown in Fig 3, after 24 hours’
incubation with VSMCs, resistin induced a decrease in both
TIMP-1 and TIMP-2 mRNA expression. The TIMP-1
mRNA levels in 10- and 40-ng/mL resistin treatment
groups were 76.1% (0.5%) (P  .001) and 87.9%
(2.6%) (P  .05) compared with the saline control; and
the TIMP-2 mRNA levels were 82.5% (2.5%) (P  .05)
and 77.3.0% (3.0%) (P  .01), respectively. Regression
analysis showed a negative and significant correlation between
resistin concentration and TIMP-2 (R .63; P .01).
Effect of MMP-2 and MMP-9 antibodies on
HCASMC migration. Neutralizing antibodies against
humanMMP-2 andMMP-9 were used to pretreat the cells
Fig 2. Effect of resistin on matrix metalloproteinase (MM
muscle cells. Resistin was tested at physiologic (10 ng/mL) a
mRNA and protein data; right panels,MMP-9mRNA and
and each bar represents the mean SEM of triplicate dete
Fig 3. Effect of resistin on tissue inhibitor metalloprot
smooth muscle cells. Resistin was tested at physiologic (
panel, TIMP-1 mRNA data; right panel, TIMP-2 mRN
each bar represents the mean  SEM of triplicate determfor 2 hours before adding resistin. Nonspecific IgG was bsed as a sham control. As shown in Fig 4, the average
umber of migrated cells in the vehicle control, resistin
lone, resistin plus nonspecific IgG, anti-MMP-2, anti-
MP-9, and anti-MMP-2 plus MMP-9 groups were 9.4
1.5), 35.0 (2.3), 32.3 (4.0), 19.3 (1.8), 12.4
1.4), and 11.1 (0.4), respectively. The data again
howed that resistin at 40 ng/mL significantly increased
ell migration, and MMP-2 and MMP-9 antibodies at a
oncentration of 10 g/mL effectively blocked resistin-
nduced SMC migration (P  .001). Nonspecific IgG
howed no similar blocking effect.
Effects of PKC on MMP, TIMP expression, and
CASMC migration. Resistin at 40 ng/mL activated
KCε, as characterized by a significant increase in membrane-
and MMP-9 expression in human coronary artery smooth
thologic (40 ng/mL) concentrations.Left panels,MMP-2
ein data. Values are expressed as percentage of the control,
tions in two to three independent experiments.
e (TIMP) mRNA expression in human coronary artery
/mL) and pathologic (40 ng/mL) concentrations. Left
a. Values are expressed as percentage of the control, and
ons in two to three independent experiments.P)-2
nd pa
proteinas
10 ng
A datound PKCε protein levels (121% of control, P  .01)
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April 20111048 Ding et al(Fig 5). Addition of selective PKCε inhibitor εV1-2 sig-
nificantly suppressed resistin-induced PKCε activation
(104.4% of the control) compared with the resistin alone
group (P  .05). The increases in MMP-2 and MMP-9
mRNA expression triggered by resistin were completely
blocked by εV1-2 (for MMP-2, from 141.2% to 93.4% of
the control, P  .001; for MMP-9, from 122.3% to 66.0%
of the control, P  .001). Interestingly, εV1-2 did not
affect resistin-induced inhibition on TIMP mRNA expres-
sion (Fig 6). To confirm the overall effect of PKCε inhibitor
on resistin-associated MMP activity, zymographic analysis
was conducted. As shown in Fig 7, resistin-induced in-
creases in MMP-2 and MMP-9 activities were completely
blocked by PKCε inhibitor. Morphologically, the migra-
tory effect of resistin on HCASMC was abolished by this
inhibitor. The average number of migrated cells decreased
Fig 4. Effect of matrix metalloproteinase (MMP)-2 and MMP-9
antibodies on resistin-induced cell migration of human coronary
artery smooth muscle cells (SMCs) (Boyden chamber assay). The
migratory effect of resistin was exerted at the concentration of 40
ng/mL. Anti-MMP-2 andMMP-9 as well as nonspecific IgG were
tested at the same concentration of 10 g/mL. Values are ex-
pressed as the number of migrated cells, and each bar represents
the mean  SEM of quadruplicate determinations.
Fig 5. Effects of resistin on protein kinase C (PKC)ε activation
and PKCε inhibitor (εV1-2) on resistin-induced PKCε activation.
Values are expressed as percentage of the control, and each bar
represents the mean  SEM of duplicate determinations in two
independent experiments.from 35.0 to 8.4 (P  .0001) (Fig 8). sISCUSSION
Long-term success of vascular bypass and angioplasty
rocedures is limited by neointimal hyperplasia and ulti-
ately restenosis, particularly in obese and diabetic pa-
ients.27,28 Matrix metalloproteinases are well known to be
nvolved in facilitating VSMCmigration, a key initial step in
eointimal hyperplasia formation. In this study, we dem-
nstrated that resistin, an elevated adipokine in obese pa-
ients with type 2 diabetes, increased vascular SMC migra-
ion through mediating MMP-2 and MMP-9 expressions,
hich themselves may be modulated by PKCε activation.
ur study provides additional evidence that resistin can
nduce vascular SMC migration. Relevant mechanistic data
n MMP and PKCε deepen our understanding on resistin-
nduced migration in human VSMCs and suggest a poten-
ial therapeutic strategy for this population of high-risk
atients.
Obesity increases the risk of cardiovascular diseases.
dipose tissue releases a large number of bioactive media-
ors, including resistin and leptin, whichmay be responsible
or those complications. For instance, Mu and colleagues
howed that resistin induced vascular endothelial cell mi-
ration in a dose- and time-dependent manner with the
aximal effect at 40 ng/mL and that resistin-induced
ndothelial cell migration could be effectively blocked by
esistin-neutralization antibody.29 Jung et al used the
crape-wound model to assess the migratory effect of resis-
in on VSMC and found that resistin at 10 ng/mL had no
igratory effect, whereas concentration of 50 ng/mL
timulated cell migration.17 In this study, we used the
oyden chamber as an alternative migration model con-
rming the migratory effect of resistin. Consistent with the
bservations of Jung et al, we found that resistin stimulated
ascular smooth muscle cell migration at a higher concen-
ration of 40 ng/mL while the lower, physiologic concen-
ration of 10 ng/mL failed to produce that effect. Consid-
ring the facts that HCASMC migrated toward the
hamber with higher concentration of resistin in the Boy-
en chamber assay, we postulated that resistin functioned
s a chemoattractant. Unlike the scrape-wound model,
oyden chamber assay is suitable for chemotactic analysis.
owever, when resistin was present at equal concentrations
n both top and bottom chambers of the Boyden chamber,
ncreased migration was also observed, which indicated
hemokinetic effects of resistin on VSMCs. Further studies
n the motility mechanisms are warranted.
Generally speaking, there are three factors directly af-
ecting cell migration: intracellular cytoskeletal rearrange-
ent, membrane molecule adhesion, and extracellular ma-
rix degradation. The first two factors were recently
eported to participate in resistin-induced VSMC migra-
ion.21 MMPs are a family of structurally related, zinc-
ontaining enzymes that degrade the extracellular matrix
nd connective tissue proteins. Among them, MMP-2 and
MP-9 appear most closely involved in VSMC migration
n vitro and intimal hyperplasia in vivo. Selective gene
ilencing of MMP-2 inhibits migration of rabbit VSMCs30
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ruption of MMP-2 gene expression32 by chemical inhibi-
tors also suppresses VSMC migration. Similarly, the block-
ade of MMP-9 expression, either by gene silencing or
chemical inhibitors, leads to the suppression of cell migra-
tion in human31,33,34 VSMCs. On the other hand, MMP-9
overexpression enhances SMC migration as shown by col-
lagen invasion and Boyden chamber assays.35 In our study,
we found that resistin induced MMP-2 and MMP-9 ex-
pressions in HCASMCs at both mRNA and protein levels.
Fig 6. Effect of protein kinase C (PKC)ε inhibitor on m
proteinase (TIMP) mRNA expressions in human coro
concentration of 40 ng/mL.Top panels,MMPmRNA d
as percentage of the control, and each bar represents the
experiments.
Fig 7. Effect of protein kinase C (PKC)ε inhibitor on
artery smooth muscle cells. Resistin was tested at the con
panel,MMP-9 activity. Values are expressed as percentag
duplicate determinations in two independent experimenOur antibody blocking experiments demonstrated that sesistin-induced VSMC migration could be suppressed by
nti-MMP-2 and anti-MMP-9 IgG, confirming that these
wo MMPs were involved in resistin-induced cell migra-
ion. It is interesting that activations of MMP-2 and
MP-9 are involved in smooth muscle cell migration in
ur in vitro model where the extracellular matrix was
bsent. We postulate that MMP-2 and -9 may facilitate
igration of VSMCs through degrading non-matrix sub-
trates. However, the significance of MMP-2 and MMP-9
ctivations remains to be determined. Our study also
metalloproteinase (MMP) and tissue inhibitor metallo-
artery smooth muscle cells. Resistin was tested at the
ottom panels,TIMPmRNA data. Values are expressed
 SEM of triplicate determinations in two independent
x metalloproteinase (MMP) activity in human coronary
ation of 40 ng/mL. Left panel,MMP-2 activity; right
he control, and each bar represents the mean SEM ofatrix
nary
ata; b
meanmatri
centr
e of thowed that resistin at lower concentration (10 ng/mL)
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possible thatmolecular changes are generally more sensitive
and respond earlier than the phenotypic change of the cells.
TIMPs are specific endogenous inhibitors that bind
MMPs in a 1:1 stoichiometry.36 The N-terminal domain of
TIMP folds as a separate unit and is capable of inhibiting
MMPs. Although TIMP-1 and TIMP-2 binds both
MMP-2 andMMP-9, TIMP-1 preferentially bindsMMP-9
and TIMP-2 preferentially binds MMP-2. Since the bio-
logic relevance of MMP expression is substantially affected
by TIMP expression, we also measured relative TIMP-1
and TIMP-2 mRNA levels after resistin treatment. We
found that while stimulating MMP expression, resistin
inhibited TIMP expression. It is possible that resistin-
induced increases in MMP-2 and MMP-9 activities in the
VSMCs were partially due to decreased TIMP. Relevant
mechanism remains to be established.
PKC is known to be involved in the regulation ofMMP
expressions in the vascular system. For example, activation
of PKC results in an increase of MMP-2 in human37
endothelial cells. Harja and associates found that activated
PKC- and increased MMP2 occurred simultaneously in
the atheroma in apoE (	/	) mice.38 Similarly, PKC-
activation induced MMP-9 secretion in human vascular
endothelial cells.39 Recently, Inagaki et al found that sus-
tained inhibition of PKCε using εV1-2 reduced perivascular
fibrosis and MMP-2 activation in a hypertension-induced
heart failure model in rats.40 εV1-2 is a water-soluble small
peptide of eight amino acids that selectively inhibits PKCε
activation by preventing the translocation of inactive PKCε
from cell cytosol to cell membrane where PKCε transforms
into the active form. In this study, we explored the poten-
tial involvement of PKCε and εV1-2 in modulating MMP
expression stimulated by resistin and demonstrated that
both PKCε activation and MMP expression occurred after
24 hours’ incubation with resistin. Furthermore, selective
Fig 8. Effect of protein kinase C (PKC)ε inhibitor on resistin-
induced cell migration of human coronary artery smooth muscle
cells (SMCs) (Boyden chamber assay). The migratory effect of
resistin was exerted at the concentration of 40 ng/mL. Values are
expressed as the number of migrated cells, and each bar represents
the mean  SEM of quadruplicate determinations.PKCε inhibitor blocked resistin-induced MMP-2 andMP-9 mRNA expression. Our study provided the first
vidence that resistin-induced VSMC migration was medi-
ted, in part, by increasedMMP-2 andMMP-9 expressions
hich, in turn, were modulated by PKCε activation. Inter-
stingly, we found that εV1-2 had no effect on resistin-
ssociated inhibition of TIMP mRNA expression, which
ndicated that PKCε was not involved in resistin-induced
nhibition of TIMP production. However, PKCεmediated
esistin-induced MMP-2 and MMP-9 expressions and ac-
ivation. Our data suggested the complex mechanism of
esistin-induced VSMC migration and that PKCε was one
f the upstream modulators regulating the effects of resis-
in.
Admittedly, the in vivo effect of resistin was not exam-
ned. However, in this mechanistic study, we confirmed
hat resistin at a pathologic concentration stimulated vas-
ular smooth muscle cell migration in vitro. Our data also
upported the hypothesis that resistin contributed to the
ntimal hyperplasia through modulating PKCε signaling
athway and upregulating MMP expressions. Selective
KCε inhibitor, εV1-2, may potentially be a more effective
herapeutic strategy in decreasing resistin-induced vascular
estenosis.
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